The Exchange had sought clarification from Medico Remedies Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.
MEDICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE had asked Medico Remedies to explain why the financial results filed for the quarter and year ended 31-Mar-2025 did not follow SEBI's prescribed format. The company clarified that the Cash Flow Statement had an incorrect header — it mistakenly said 'Statement of Assets and Liabilities' instead of 'Cash Flow Statement'. The company has now submitted revised financial results with the correct header. The auditor (VJ Shah & Co) has issued an unmodified opinion on the results. Key financials show FY25 revenue from operations of Rs 15,094 lakhs (up from Rs 14,492 lakhs), and profit after tax of Rs 1,009 lakhs (up from Rs 829 lakhs), a growth of about 22%. Q4 revenue stood at Rs 4,130 lakhs with PAT of Rs 434 lakhs. EPS for FY25 was Rs 1.22 versus Rs 1.00 in FY24.
This is a minor administrative labelling error that has been corrected — no financial numbers were changed and no penalty or adverse action was imposed. Investors should not read this as a red flag; the underlying business performance shows steady growth in revenue and profits.